Safeguard Scientifics’ Aggregate Partner Company Revenue Guidance Resonating with Potential Investors
Posted by | March 19, 2010
After spending the better part of the past two weeks meeting with money managers in financial centers throughout the Midwest and Southeast, it seems to me that potential investors are intrigued by Safeguard Scientifics‘ aggregate partner company 2010 revenue guidance.
Safeguard projects aggregate partner company revenue for 2010 in the range of $300 million to $325 million. In 2009, Safeguard reported aggregate partner company revenue of $262 million as compared to $179 million in 2008 and $100 million in 2007. Terrific growth during a few years that many deemed difficult! As a result, our message is beginning to resonate and investors seem to understand Safeguard’s growth potential.
For example, last week Safeguard partner company Advanced BioHealing (ABH) discussed its diversified regenerative medicine model and its lead product Dermagraft at the Canaccord Adams Musculoskeletal Conference.
ABH highlighted that revenues increased to approximately $85 million in 2009, up from $7 million in 2007. The company projects that revenues in 2010 will exceed $120 million. ABH is the emerging leader in regenerative medicine. The company has brought to market an approved product with strong clinical data and reimbursement fundamentals, and developed a growing revenue stream to fuel organic and non-organic growth.
I am very excited about the prospects of both Safeguard and Advanced BioHealing.
